Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Ensartinib (X-396)

Agent Description

Ensartinib is a small molecule, ALK inhibitor that potently inhibits ALK and most of its alternations (fusions, mutants). It is also a potent EphA2 inhibitor with modest selectivity with respective to other Ephrin isoforms. It is orally bioavailable and supplied in capsules.

Mechanism of Action

Inhibition of ALK, whose aberration causes cancers

Classification

ALK inhibitor

Molecular Target

ALK, TrkA, TrkC, ROS, EphA2, c-MET

Monograph

Ensartinib has shown very good efficacy in ALK positive non-small cell lung cancer (NSCLC) patients whose cancer progressed on crizotinib in the Phase 1/2 trial. Currently, it is in Phase 3 trial comparing to crizotinib in patients with ALK-positive NSCLC.

Studies of Interest

New indications as an ALK inhibitor, EphA2 inhibitor. Combination studies.

Information collaborator would like included in investigator proposals

N/A

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Ensartinib (X-396) was originally published by the National Cancer Institute.”

Email